To investigate the association between lean mass (LM) and fat mass (FM) with fatigue and vitality before and after exercise in patients with prostate cancer already undergoing androgen-deprivation therapy (ADT).
Objectives
To investigate the association between lean mass (LM) and fat mass (FM) with fatigue and vitality before and after exercise in patients with prostate cancer already undergoing androgen-deprivation therapy (ADT).
Subjects and Methods
Cross-sectional associations between LM and FM with fatigue and/or vitality measures were examined in 229 patients (aged 43-90 years). Prospective analysis was undertaken in 129 patients who underwent a supervised 3-6 months exercise programme (predominantly resistance + aerobic). Whole body and appendicular LM, and total and trunk FM were assessed by dual X-ray absorptiometry. Fatigue was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-30) and vitality using the Short Form-36.
Results
Based on the EORTC QLQ-30, 19% of patients had clinically relevant fatigue. There was no association between LM and fatigue; however, total (P = 0.013), trunk (P = 0.015) and percentage (P = 0.008) FM were higher in fatigued than not fatigued patients, with total and trunk FM 5.0 and 2.6 kg higher, respectively. For quartiles of vitality, a similar pattern emerged for FM with those in the lowest quartile of vitality having the highest FM values (P = 0.014-0.034). In contrast, following supervised exercise, change in fatigue and vitality were associated with change in total LM (r = À0.182, P = 0.042 and r = 0.309, P = 0.001, respectively) but not FM. Patients fatigued at baseline but not fatigued following the exercise programme gained a median (interquartile range) of 2.1 (0.7-3.2) kg LM.
Introduction
Prostate cancer is the most commonly diagnosed cancer amongst men [1] . For those with locally advanced prostate cancer, long-term androgen-deprivation therapy (ADT) combined with radiotherapy is standard treatment [2] . Whilst long-term ADT treatment results in a survival benefit [2] , patients on ADT experience a range of side-effects that include decreased bone mineral density and lean mass (LM), increased fat mass (FM), sexual dysfunction, and fatigue [3] .
Fatigue becomes an increasingly prevalent issue in patients with prostate cancer resulting from ADT. The prevalence of clinically relevant fatigue in patients undergoing ADT increases within the first 6 months of commencing treatment before reaching a plateau at~12 months [4, 5] . Nelson et al. [5] reported that 30% of men had a clinically meaningful change in fatigue in the first 6 months of treatment, whilst in a group of patients with a median ADT treatment duration of 22 months, 43% had clinically relevant fatigue [6] . Consequently, strategies are needed to prevent or manage fatigue in this population.
It has recently been suggested that muscle mass may be an important target for reducing cancer-related fatigue [7] . In two studies, which included patients with advanced cancer, higher skeletal muscle mass was associated with lower fatigue scores in men [7, 8] . In addition to a reduction in muscle mass, patients on ADT also experience a substantial increase in FM [9] . However, there is a paucity of information on the relationship between FM and fatigue in cancer populations. One study in women with breast cancer reported a significant, albeit weak, correlation between percentage body fat and fatigue [10] ; however, another study reporting on this relationship in patients with breast cancer did not find a significant association [11] . Although findings to date are mixed, these results do raise the possibility that addressing increases in FM may also be an important target for the management of cancer-related fatigue.
Resistance exercise results in significant improvements in body composition and fatigue for patients on ADT, with a recent meta-analysis reporting a significant average increase in LM of 1 kg [12] . Further, patients who completed resistance training lost an average of 0.4 kg trunk FM, although there was no significant reduction in total FM [12] . With regards to fatigue, several studies have reported resistance exercise [13] or combined resistance and aerobic exercise [14] [15] [16] to result in improvements in fatigue scores in patients with prostate cancer treated with ADT. Whether improvements in fatigue are associated with changes in body composition has not been examined but would provide an interesting insight into the mechanisms behind cancer-related fatigue, which remain poorly understood.
Our aim in the present study was to investigate the relationship between body composition and fatigue in patients with prostate cancer receiving ADT. In addition, we examined the relationship between body composition and vitality, which is a measure of energy level and fatigue. Further, for patients who undertook supervised exercise training, we explored if there was an association between change in body composition and change in fatigue and vitality after exercise.
Patients and Methods

Participants
In all, 229 men with a histological diagnosis of prostate cancer, already treated with ADT were included from three published randomised controlled trials undertaken in the Exercise Medicine Research Institute at Edith Cowan University, Australia as outlined in Fig. 1 [14] [15] [16] . Eligible patients were anticipated to remain on ADT for 3 [14] , 6 [15] , or 12 months [16] . Exclusion criteria included presence of bone metastases, being unable to walk 400 m unassisted, musculoskeletal, cardiovascular and/or neurological disorders that could inhibit them from exercising (as determined by the treating physician). Two studies specified that patients must have had a minimum exposure to ADT of 2 months and without PSA evidence of disease activity [15, 16] , whilst the third study included patients commencing ADT [14] . Edith Cowan University Human Research Ethics Committee approved all studies and all patients provided written informed consent.
Cross-sectional and prospective analyses were undertaken. For the cross-sectional analysis, we examined the association between LM and FM with fatigue and/or vitality measures in the 229 patients. To ensure all patients had been treated with ADT for a minimum of 2 months, baseline data from the two exercise trials with patients on ongoing ADT [15, 16] or the 3-month assessment for patients assigned to delayed intervention for patients commencing ADT [14] were used. Prospective analysis was conducted on 129 patients to examine changes following exercise training. This included patients from the three studies treated for at least 2 months with ADT who underwent exercise training. All patients remained on ADT during the exercise intervention.
Exercise Interventions
Supervised exercise training was undertaken twice weekly for 3 [14, 15] or 6 months [16] in small groups of up to 10 patients. The exercise training involved: (i) resistance training exercises that targeted the major muscles of the upper and lower body, with 2-4 sets of each exercise performed at an intensity of 6-12 repetition maximum (the maximum weight that could be lifted 6-12 times), and (ii) aerobic exercise for 20-30 min performed at 60-75% of estimated maximal heart rate. In the third arm of one study [16] , patients underwent resistance exercise but instead of undertaking aerobic exercise completed impact loading training (e.g., jumping, bounding, hopping) that is described in detail elsewhere [17] .
Outcome Measures
Body Composition
Whole body and regional LM and FM, and percentage fat were derived by dual-energy X-ray absorptiometry (DXA; Hologic Discovery A, Waltham, MA, USA) at baseline and following the exercise intervention. Appendicular LM was derived from the sum of upper-and lower-limb LM [18, 19] .
Fatigue and Vitality
Fatigue was assessed at baseline and following the exercise intervention in all studies using the three-item subscale from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire -Core 30 (EORTC QLQ-C30), with higher scores indicating greater fatigue [20] . Clinically relevant fatigue was classified as an EORTC QCQ-30 fatigue subscale score of >39 [21] . Vitality was assessed using the four-item sub-scale of the Short-Form 36 (SF-36) Health Survey [22] . Scores for vitality ranged from 0 to 100, with higher scores reflecting more vitality. Both questionnaires are well validated and extensively used in the exercise and cancer literature [23, 24] .
Statistical Analyses
Statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS â ) version 23 (SPSS Inc., IBM Corp., Somers, NY, USA). Demographic and clinical data were expressed as mean (SD) for continuous data or median and interquartile range (IQR) for data not normally distributed, and as number and percentage for categorical variables. Patients were grouped as fatigued or not fatigued based on their EORTC fatigue score (i.e., >39 or ≤39) [21] . For vitality, patients were grouped according to quartiles, as no clinically relevant thresholds are available. For the prospective analysis, patients were also grouped according to changes in LM following supervised exercise training (i.e., gained or lost LM). We also examined four different categories of fatigue; (i) not fatigued at baseline -not fatigued at post-test; (ii) fatigued at baseline -not fatigued at posttest; (iii) not fatigued at baseline -fatigued at post-test; and (iv) fatigued at baseline -fatigued at post-test.
To examine the relationship between body composition and fatigue at baseline and changes in body composition and fatigue and vitality with the prospective data, the MannWhitney test was used, or where the data were normally distributed, independent t-tests were used. When the patients were grouped into quartiles to examine the association between body composition and vitality at baseline and vitality and fatigue in the prospective analysis the Kruskal-Wallis test was applied. Spearman's correlations were used to assess the 
Results
Patient Characteristics
Patient characteristics are presented in Table 1 . The patients were aged 43-90 years with a median (IQR) time on ADT of 3.0 (2.0-6.0) months and range of 2-156 months. Indications for ADT were almost solely PSA failure after primary treatment of radiation therapy or surgery or combination. No patients had bone metastases. For all patients, testosterone withdrawal was achieved through chemical means and involved a LHRH agonist, with approximately half (49.3%) also taking an antiandrogen. Only 17 patients (7.4%) had been on ADT for ≥12 months. With regards to other treatments, a quarter of patients (26.6%) had undergone a prostatectomy, whilst one-fifth (22.3%) had received radiotherapy. In all, 90% of the patients had a Gleason score of 7-9. The majority of patients were either overweight (54.1%) or obese (30.1%), with about half reporting one or more co-morbidities. Treatment with ADT had the desired effect with the patients' median (IQR) PSA levels being 0.41 (0.05-1.53) ng/ mL and testosterone levels of 0.80 (0.00-1.30) ng/mL.
Cross-Sectional Analysis of Body Composition and Fatigue
At baseline, one in five (19.3%) patients had clinically relevant fatigue. Cross-sectional analysis of body composition variables according to fatigue status are presented in Table 2 . 
Cross-Sectional Analysis of Body Composition and Vitality
When the patients were grouped into quartiles of vitality (Table 3) there were significant differences amongst groups for total FM, trunk FM and percentage body fat (P = 0.034, P = 0.014 and P = 0.026, respectively). The patients who scored in the lowest quartile for vitality (that is, the poorest vitality) had the highest total FM, trunk FM and percentage body fat values. There were no significant differences between groups for total LM or appendicular LM as absolute values (P = 0.166 and P = 0.165, respectively) or relative to height (P = 0.599 and P = 0.406, respectively).
Changes in Fatigue Scores Following Supervised Exercise Training and Its Relationship with Body Composition Changes
There was a significant inverse, yet modest, correlation between change in fatigue score and change in total LM over the exercise interventions (r = À0.182; P = 0.042, Fig. 2A ), that is, as LM increased fatigue was reduced. However, there were no significant correlations between change in fatigue score and any of the other body composition variables. When examining changes in body composition based on fatigue status at baseline and following supervised exercise there was a significant difference between fatigue categories for change and total LM (P = 0.029), but not for appendicular LM, trunk FM, total FM or percentage body fat, such that those fatigued at baseline but not fatigued following training had a median (IQR) increase in total LM of 2.1 (0.7-3.2) kg (Table 4) .
Changes in Vitality Scores Following Supervised Exercise Training and Its Relationship with Body Composition Changes
There was a significant correlation between change in vitality score and change in total LM (r = 0.309, P = 0.001; Fig. 2B ), such that as LM increased so too did vitality. There were no significant correlations found between change in vitality score and any of the other body composition changes. Patients who lost LM had a 5-point median decrease on the vitality subscale, whilst those who gained LM had a 5-point median increase in their vitality score, at a median (IQR) of À5.6 (À12.5 to 6.3) vs 5.00 (À2.5 to 12.5; P = 0.007).
When the patients were divided into quartiles based on vitality score change, there was a significant difference among quartiles only for total LM (P = 0.031; Table 5 ). Patients in the highest quartile for vitality change score (i.e., had the most improvement in vitality) gained a median (IQR) of 0.60 (0.08-2.05) kg of LM, whilst those in the lowest quartile lost 0.11 (À1.02 to 0.72) kg of LM.
Discussion
In the present study, we examined the cross-sectional and prospective associations between LM and FM with fatigue and vitality in patients with prostate cancer undergoing ADT. There were two important findings: (i) total body FM, as well as trunk FM, were substantially higher in patients with clinically relevant fatigue with a similar pattern for those with the lowest vitality; and (ii) following 3-6 months of predominantly resistance and aerobic exercise, change in fatigue and vitality was associated with change in LM, such that patients who gained the most LM were also no longer fatigued. As a result, targeting change in LM and FM by appropriate exercise medicine may be one way to reduce clinically relevant fatigue in patients with prostate cancer on ADT.
Contrary to recent reports [7, 8] we found FM and not LM, either total body or appendicular LM, which represents limb 
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© 2018 The Authors BJU International © 2018 BJU International muscle mass, in absolute terms or adjusted for height, to be associated with clinically relevant fatigue in our present cohort of untrained patients on ADT. The adipose differences we found between fatigued and not fatigued patients were substantial and represent an increased FM of 22% and 21% for the total body and trunk, respectively. In a similar fashion, those with the lowest vitality had the highest total and trunk FM values. An association of adiposity and fatigue Table 4 Change in LM and FM after supervised exercise training amongst four fatigue categories.
Fatigue group* P Change in vitality score* P in breast cancer survivors has been reported by WintersStone et al. [10] , as well as in non-cancer populations [25, 26] , although others have not found this relationship in breast cancer survivors [11] . Increased FM and the associated production of pro-inflammatory cytokines [27] may augment the pro-inflammatory effects of cancer leading to peripheral and central alterations that may contribute to cancer-related fatigue [28] .
However, following exercise a different association emerged in our present cohort of patients with change in LM associated with change in fatigue and vitality. Moreover, those no longer fatigued after the exercise intervention had the greatest increase in whole body LM. Consequently, targeting muscle and fat tissue with exercise, that is augmenting LM, may have positive effects on fatigue and vitality in patients with prostate cancer undergoing ADT. In a cross-sectional investigation, Kilgour et al. [8] initially reported that skeletal LM determined by DXA was associated with cancer-related fatigue in men with advanced gastrointestinal or non-small cell lung cancer but not in women, with fatigue decreasing with increasing LM. Similarly, Neefjes et al. [7] in a crosssectional study of patients with advanced cancer with lung, colorectal, breast or prostate cancer commencing palliative chemotherapy reported that a higher skeletal LM at the level of L3 measured by CT and adjusted for height was associated with less cancer-related fatigue in men but not women. The authors [7] concluded that the apparent sex difference in the association may be due to cancer-related fatigue in women being more influenced by other factors not related to LM, while Kilgour et al. [8] proposed that differences in body mass index and circulating sex hormones may be responsible for the sex difference. In any event, the studies by Neefjes et al. [7] and Kilgour et al. [8] combined with the results of our present prospective analysis indicates that there is an apparent association between cancer-related fatigue status and LM in men.
Fatigue remains a significant adverse side-effect for patients undergoing ADT and within the medical clinical area, and unfortunately rest therapy continues to be commonly recommended despite current international guidelines [29] . Our present findings reassure concerned clinicians that augmenting LM with targeted exercise may be one strategy to counter fatigue in patients with prostate cancer undergoing ADT. Of the various exercise modes, resistance exercise especially when performed at a moderate-to highintensity is an anabolic activity that can result in substantial skeletal muscle hypertrophy, as well as the enhancement of muscle function (muscle strength, power, and endurance) [30] . We have shown in a number of studies [14] [15] [16] 31] in patients with prostate cancer undertaking ADT, which has a catabolic effect on LM due to the hypogonadal state that results from this form of treatment, that supervised resistance training can lead to LM accretion, as well as substantial changes in muscle strength and physical function. Combined with an increase in energy expenditure by undertaking aerobic exercise, positive body composition adaptations of enhancement of LM and reduction in FM may result from a multimodal exercise regimen that combines resistance and aerobic exercise leading to a reduction in cancer-related or clinically relevant fatigue in patients with cancer, and this should be recommended for men undergoing ADT. Low LM and muscle strength translates to tasks of daily living being performed close to the threshold for functional capacity, requiring high exertion and exacerbating fatigue. By increasing functional capacity [32] , such tasks are relatively easier and may explain the relationship between exercise training-induced reduction in fatigue and improved vitality.
The present study has several strengths and limitations that are worthy of comment. First, our present cohort includes a large number of patients, 229 in total, who had been on ADT for ≥2 months and had body composition determined by DXA, permitting assessment of whole body and regional LM and FM. Second, a considerable number of these patients (129 in total) underwent a supervised exercise programme for 3-6 months duration. Third, fatigue was assessed using the EORTC QLQ-C30 fatigue subscale, which is a validated, widely used, and a recommended instrument in trials assessing cancer-related fatigue [24] . A limitation needs to be noted that the patients were volunteers for exercise trials and met specific inclusion criteria and, as such, were generally healthy and may not be representative of all patients with prostate cancer undergoing ADT. Only 19.3% of patients in the present study were classified as clinically fatigued, which is substantially lower than the 30-43% reported by Nelson et al. [5] and this may reflect their better general health and willingness to exercise.
In conclusion, we found that body composition is associated with fatigue and to a lesser extent vitality in patients with prostate cancer on ADT. Although the relationship differs somewhat before or after exercise, the study does provide evidence that targeting change in body composition with exercise may assist in reducing fatigue in this patient group. Moreover, specifically targeting LM accretion with appropriate exercise in patients with clinically relevant fatigue may substantially reduce their fatigue thereby enhancing their quality of life. Consequently, clinicians should be advising patients on ADT with cancer-related fatigue to undertake exercise, specifically resistance exercise, to potentially alleviate their fatigue and refer them to exercise professionals, such as exercise physiologists, in order for appropriate programmes to be implemented.
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